Get out your popcorn – things are about to get interesting at Atlas Arteria. IFM Investors, a 35 per cent shareholder, is expected to announce what appears to be a “best and final” bid on Monday for ...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...

IFM Investors moved on Atlas Arteria with a $6.9 billion buyout bid after the ASX-listed toll road operator indicated it would not listen to its largest shareholder and consider pursuing an expensive ...

IFM Global Infrastructure Fund offers A$4.75 per Atlas share Offer price at 9.7% premium to Atlas Arteria's last close Atlas Arteria shares log strongest session since June 8, 2022 April 27 (Reuters) ...

Find the latest (IFM.TO) stock quote, history, news and other vital information to help you with your stock trading and investing.